(Q38028124)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

title

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

main subject

phase II clinical trial

0 references

1 reference

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Andrea Necchi

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Luigi Mariani

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Nadia Zaffaroni

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Carlo Morosi

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Rodolfo Lanocita

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Marzia Pennati

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Maria Grazia Daidone

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Nicola Nicolai

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Roberto Salvioni

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

author name string

Lawrence H Schwartz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Patrizia Giannatempo

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Flavio Crippa

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Teodoro Sava

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Cinzia Ortega

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Caterina Messina

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Cosimo Sacco

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

Alessandro M Gianni

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

publication date

20 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

Lancet Oncology Commission

8 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

volume

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

page(s)

810-816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

Advanced bladder cancer: status of first-line chemotherapy and the search for active agents in the second-line setting

8 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

VEGF receptor expression and signaling in human bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Hypoxia-inducible factor and mammalian target of rapamycin pathway markers in urothelial carcinoma of the bladder: possible therapeutic implications

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Evaluation of hypoxia-inducible factor 1alpha overexpression as a predictor of tumour recurrence and progression in superficial urothelial bladder carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

(Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

A note on quantifying follow-up in studies of failure time

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Tumor angiogenesis correlates with lymph node metastases in invasive bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Quantification of angiongenesis as an independent predictor of prognosis in invasive bladder carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Phase II study of sunitinib in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Phase II study of everolimus in patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract: clinical activity, molecular response, and biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970294-2

7 January 2021

10.1016/S1470-2045(12)70294-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22819172%20AND%20SRC:MED&resulttype=core&format=json

8 February 2020

1 reference